RxDoctor Payments Data

Keith Ridel, MD

Neurology with Special Qualifications in Child Neurology · Indianapolis, INNPI 1053528935

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Eisai Inc. accounts for 67.3% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $77,068 and has fallen 93.0% since, to $5,372 in 2025. Among neurology with special qualifications in child neurology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$110,067in general payments, 2019–2025

Across 1,969 payments — averaging $55.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$74K
  • AbbVie$6K
  • UCB, Inc.$4K
  • Jazz Pharmaceuticals Inc.$2K
  • SK Life Science, Inc.$2K
  • Novartis$1K
  • plus $21K from 54 others
$352,356in research payments, 2019–2025

Across 67 payments — averaging $5259.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$215K
  • Eli Lilly$134K
  • Arbor Pharmaceuticals, Inc.$3K

What the payments were for

  • Consulting fees$5,3705%
  • Speaking & faculty fees$50,01945%
  • Travel & lodging$15,18614%
  • Food & beverage$39,48036%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.167$74,085
AbbVie(2 entities)302$5,722
UCB, Inc.256$3,894
Jazz Pharmaceuticals Inc.49$1,905
SK Life Science, Inc.64$1,891
Novartis110$1,440
Livanova USA, Inc.29$1,315
Biohaven Pharmaceuticals, Inc.56$1,226
Amgen(2 entities)28$1,173
Pfizer62$1,147
Neurocrine Biosciences, Inc.41$993
Neurelis, Inc.41$923
AstraZeneca(2 entities)27$886
Biohaven Pharmaceutical Holding Company Ltd.59$836
Lilly USA, LLC59$835
Biogen39$769
Greenwich Biosciences, Inc.20$748
Acadia Pharmaceuticals Inc25$714
Supernus Pharmaceuticals, Inc.97$650
MDD US Operations, LLC23$648
Sanofi31$638
Sunovion Pharmaceuticals Inc.50$586
EMD Serono, Inc.29$404
Catalyst Pharmaceuticals, Inc.22$403
Genentech USA, Inc.24$397
Teva Pharmaceuticals USA, Inc.23$333
Argenx US, Inc.16$327
Amneal Pharmaceuticals LLC14$283
CSL Behring14$281
Banner Life Sciences, LLC12$265
Lundbeck LLC12$263
TG Therapeutics, Inc.12$260
Acorda Therapeutics, Inc20$240
Axsome Therapeutics, Inc.7$234
Medtronic4$214
Takeda Pharmaceuticals U.S.A., Inc.9$207
Zogenix Inc.4$198
Alnylam Pharmaceuticals Inc.8$168
Sumitomo Pharma America, Inc.9$166
Vanda Pharmaceuticals Inc.6$163
Avanir Pharmaceuticals, Inc.9$156
Akcea Therapeutics, Inc.1$150
Biocodex, Inc.3$150
Mallinckrodt Hospital Products Inc.3$138
Grifols USA, LLC6$130
Tris Pharma Inc1$122
Tanabe Pharma America, Inc.5$106
Collegium Pharmaceutical, Inc.1$106
Aquestive Therapeutics, Inc.6$95
Neuropace, Inc.1$93
Johnson & Johnson4$82
Otsuka America Pharmaceutical, Inc.4$73
GRT US Holding, Inc.3$70
Azurity Pharmaceuticals, Inc.4$66
PTC Therapeutics, Inc.2$61
Aprecia Pharmaceuticals, LLC3$54
Ipsen Biopharmaceuticals, Inc3$50
Upsher-smith Laboratories LLC3$48
Mallinckrodt Enterprises LLC2$46
Springworks Therapeutics, Inc.2$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,067 in reported general payments places this provider in the 95th percentile of 25 neurology with special qualifications in child neurology providers in Indiana.

See all neurology with special qualifications in child neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$140,025
Medicare patients
482
Services billed
1,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$140,066
EpidiolexCannabidiol (Cbd)17$43,661
Lacosamide27$4,282
Levetiracetam31$992
Oxcarbazepine15$917
ClopidogrelClopidogrel Bisulfate18$236
Atorvastatin Calcium26$178
Lamotrigine11$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$281$140,06612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 neurology with special qualifications in child neurology providers in Indiana.

Other neurology with special qualifications in child neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →